Trevi Therapeutics (NASDAQ:TRVI) Given New $25.00 Price Target at Needham & Company LLC

Trevi Therapeutics (NASDAQ:TRVI) had its target price boosted by Needham & Company LLC from $8.00 to $25.00 in a research report released on Monday morning, Marketbeat Ratings reports. Needham & Company LLC currently has a buy rating on the stock.

Several other research firms have also recently issued reports on TRVI. HC Wainwright lifted their price objective on shares of Trevi Therapeutics from $6.00 to $7.50 and gave the company a “buy” rating in a research report on Thursday, December 12th. D. Boral Capital restated a “buy” rating and issued a $21.00 price target on shares of Trevi Therapeutics in a research report on Friday, March 7th. Seven analysts have rated the stock with a buy rating and three have given a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Buy” and a consensus price target of $15.94.

Trevi Therapeutics Price Performance

Trevi Therapeutics stock opened at $6.30 on Monday. The stock has a market cap of $484.26 million, a P/E ratio of -14.32 and a beta of 0.90. Trevi Therapeutics has a 1 year low of $2.30 and a 1 year high of $7.39. The firm’s 50 day moving average price is $4.26 and its 200-day moving average price is $3.58.

Insider Buying and Selling

In other Trevi Therapeutics news, insider Farrell Simon sold 81,313 shares of the business’s stock in a transaction on Monday, March 10th. The shares were sold at an average price of $6.75, for a total transaction of $548,862.75. Following the transaction, the insider now owns 76,900 shares in the company, valued at $519,075. The trade was a 51.39 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. 24.37% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the company. Frazier Life Sciences Management L.P. increased its position in Trevi Therapeutics by 44.5% during the fourth quarter. Frazier Life Sciences Management L.P. now owns 10,664,774 shares of the company’s stock valued at $43,939,000 after acquiring an additional 3,283,684 shares during the last quarter. Point72 Asset Management L.P. bought a new position in Trevi Therapeutics during the fourth quarter valued at $17,099,000. Vivo Capital LLC increased its position in Trevi Therapeutics by 116.3% during the fourth quarter. Vivo Capital LLC now owns 3,487,903 shares of the company’s stock valued at $14,370,000 after acquiring an additional 1,875,000 shares during the last quarter. Woodline Partners LP increased its position in Trevi Therapeutics by 429.9% during the fourth quarter. Woodline Partners LP now owns 3,212,597 shares of the company’s stock valued at $13,236,000 after acquiring an additional 2,606,370 shares during the last quarter. Finally, MPM Bioimpact LLC boosted its stake in shares of Trevi Therapeutics by 101.2% during the fourth quarter. MPM Bioimpact LLC now owns 3,094,896 shares of the company’s stock valued at $12,751,000 after purchasing an additional 1,556,379 shares during the period. Institutional investors own 95.76% of the company’s stock.

About Trevi Therapeutics

Trevi Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems.